Portable Screening Test For Tuberculosis
A Key Requirement To Eradicate a Global Pandemic
Epilab's state of the art technology helps health organisation that want to fight tuberculosis by improving the rate of diagnosis in developing countries and reducing the number of new infections and victims.
Tuberculosis In Figures
10 Million New Cases Each Year
Each year, 10 million people contract tuberculosis. One-third of these new cases, representing about 3 million individuals, are not detected and remain unknown to health organisations. As a result, patients are not receiving appropriate treatment, thereby allowing for ongoing disease transmission.
4 Million Undetected Cases
Eighty percents of new yearly cases emerge in developing countries that lack resources to implement successful diagnosis campaigns. Existing tests are not adapted to the needs of those countries.
4 in10 people with tuberculosis
are not diagnosed or treated
1.5 Million Victims
Despite being a preventable and curable disease, 1.5 million people die from tuberculosis each year because their diagnosis is “missed,” making it the world’s top infectious disease killer.
The main reason of this underdiagnosis are:
Infrastructure (labs) required : most of the population does not have easy access to the few existing infrastructures
Medically qualified staff required
Testing is expensive.
Available tests are unquantifiable and lack sensitivity
epilab screening Test
The answer to underdiagnosis of Tuberculosis in developing countries
No infrastructure needed
Adapted to affected countries
Matches WHO's demand
Easy To Use
No qualification needed
Competitive with existing tests
How We Do It?
We leverage a patented tuberculosis detection method using specific enzymatic reactions coupled with electrochemical detection.
To learn more about EpiLAB patented technology send us a message by clicking the button below.
They Support Us
Get In Touch
Meeting Frédérique Vidal, at Viva Technology event
Viva technology, Europe's biggest startup and tech event, was organised in june 2021 in Paris. Epilab had the opportunity to present its solution on a stand and meet several potential partners.
Special thanks to Frederic Vidal, Minister of Higher Education, Research and Innovation, to whom we presented the EpiLAB solution.
Deeptech Connect event in Paris
Epilab had the opportunity to exchange with the Deeptech ecosystem during the Deeptech Connect. A very interesting day where multiple actors from multiples domains, related to deeptech, gathered.
Epilab joins Cerba Healthcare's virtual incubator
By joining the Virtual Incubator of Cerba HealthCare Group, already widely established in Africa, EpiLAB will be able to accelerate the development of its test and its widespread use. The collaboration with Cerba HealthCare will allow Epilab to propose a product as close as possible to the needs of the field, in order to facilitate its adoption by healthcare professionals and optimize its integration into new patient pathways.
On December 14th was held 13th DemoDay 13 the X-Novation Center from École Polytechnique. EpiLAB had the opportunity to pitch in front of a selected panel of investors and mentors.
Special thanks to the whole ecosystem for the amazing support!
1M€ seed to develop Epilab kit
Epilab raises €1 million to develop its portable, simple and rapid tuberculosis diagnostic kit. This kit will be the first to answer the international's demand for a such a screening tool, and will be deployed in West Africa.
Interview with Epilab at France biotech
France Biotech is the French trade association of biotechnology companies. Its primary mission is to support the development of this industry in France.
Epilab was the subject of the 5th episode of its "Pépites Healthtech" series where France Biotech present promising start-ups.